- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lupin acquires Russian drug firm Biocom
Lupin, India's fifth largest drug maker, has entered the Russian market by acquiring 100% stake in Biocom, a fast-growing generic pharmaceuticals firm, for an undisclosed amount. "Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets," said Vinita Gupta, CEO at Lupin.The acquisition marks Mumbai-based firm's entry into the...
Lupin, India's fifth largest drug maker, has entered the Russian market by acquiring 100% stake in Biocom, a fast-growing generic pharmaceuticals firm, for an undisclosed amount. "Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets," said Vinita Gupta, CEO at Lupin.
The acquisition marks Mumbai-based firm's entry into the Russian pharmaceutical market which recorded RUB 765 billion in sales.
The acquisition marks Mumbai-based firm's entry into the Russian pharmaceutical market which recorded RUB 765 billion in sales.
Next Story